retatrutide peptide triple hormone receptor agonist The power of three: Retatrutide's role in modern obesity and diabetes therapy What Is Retatrutide? Complete Research

Taking GLP-1

The logic is that lower doses lead to milder side effects

However, when patients stop taking these drugs, they not only regain weight, but, according to a new study, they also incur increased risk of heart attack, stroke and death compared to staying on the medication

Meta-analyses of randomized trials corroborate these findings: one large review of 27 RCTs reported no significant difference in suicidality between GLP-1 RAs and placebo (RR 0.76) [48], while another meta-analysis including 25 trials similarly showed no association across multiple subgroups and endpoints (RR 0.84) [49]

Research suggests patients using medical weight loss drugs are increasingly seeking treatments for facial volume loss and other appearance changes